High‐level ceftaroline resistance in a paediatric patient with invasive methicillin‐resistant Staphylococcus aureus infection without previous ceftaroline exposure
| Autor: | Mallory C Cowart, Federico R. Laham, Chelsea L Ferguson, Alejandro Jordan-Villegas |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry MRSA infection medicine.disease medicine.disease_cause 030226 pharmacology & pharmacy Methicillin-resistant Staphylococcus aureus 03 medical and health sciences 0302 clinical medicine Staphylococcus aureus Internal medicine medicine Vancomycin Endocarditis Pharmacology (medical) In patient 030212 general & internal medicine business Myositis medicine.drug Paediatric patients |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 46:524-527 |
| ISSN: | 1365-2710 0269-4727 |
| DOI: | 10.1111/jcpt.13316 |
| Popis: | What is known an objective Our objective is to report a paediatric case of high-level ceftaroline resistance without previous ceftaroline exposure. Case description A 20-month-old, 12 kg, female with invasive MRSA infection presented with high-level ceftaroline resistance with no previous ceftaroline exposure. What is new and conclusion To our knowledge, our case is the first report of high-level ceftaroline resistance evident in a paediatric patient with invasive infection due to MRSA, without history of prior ceftaroline exposure. This case illustrates the importance of weighing the risk of resistance with the benefits of use when starting therapy empirically prior to susceptibility results, even in patients without previous drug exposure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|